A detailed history of China Universal Asset Management Co., Ltd. transactions in Novo Cure LTD stock. As of the latest transaction made, China Universal Asset Management Co., Ltd. holds 20,580 shares of NVCR stock, worth $347,184. This represents 0.04% of its overall portfolio holdings.

Number of Shares
20,580
Previous 20,580 -0.0%
Holding current value
$347,184
Previous $322,000 0.31%
% of portfolio
0.04%
Previous 0.04%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 29, 2024

BUY
$12.42 - $17.29 $102,055 - $142,071
8,217 Added 66.46%
20,580 $322,000
Q4 2023

May 21, 2024

SELL
$11.13 - $15.78 $91,455 - $129,664
-8,217 Reduced 39.93%
12,363 $184,000
Q4 2023

Jan 23, 2024

BUY
$11.13 - $15.78 $107,115 - $151,866
9,624 Added 351.37%
12,363 $185,000
Q3 2023

May 21, 2024

BUY
$16.15 - $42.35 $21,754 - $57,045
1,347 Added 96.77%
2,739 $44,000
Q3 2023

Oct 30, 2023

BUY
$16.15 - $42.35 $21,754 - $57,045
1,347 Added 96.77%
2,739 $44,000
Q2 2023

May 21, 2024

SELL
$40.29 - $82.51 $1,490 - $3,052
-37 Reduced 2.59%
1,392 $57,000
Q2 2023

Jul 27, 2023

SELL
$40.29 - $82.51 $1,490 - $3,052
-37 Reduced 2.59%
1,392 $58,000
Q1 2023

May 21, 2024

BUY
$56.44 - $118.81 $20,487 - $43,128
363 Added 34.05%
1,429 $85,000
Q1 2023

Apr 27, 2023

BUY
$56.44 - $118.81 $20,487 - $43,128
363 Added 34.05%
1,429 $86,000
Q4 2022

May 21, 2024

SELL
$63.98 - $85.37 $1.25 Million - $1.67 Million
-19,514 Reduced 94.82%
1,066 $78,000
Q4 2022

Jan 31, 2023

BUY
$63.98 - $85.37 $5,438 - $7,256
85 Added 8.66%
1,066 $78,000
Q3 2022

Oct 21, 2022

BUY
$67.99 - $89.57 $66,698 - $87,868
981 New
981 $75,000

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $1.77B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track China Universal Asset Management Co., Ltd. Portfolio

Follow China Universal Asset Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.